NASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Short Interest Ratio & Short Volume $24.89 +0.03 (+0.12%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$24.41▼$25.0350-Day Range$24.64▼$41.7352-Week Range$23.03▼$76.36Volume129,061 shsAverage Volume241,133 shsMarket Capitalization$524.18 millionP/E RatioN/ADividend YieldN/APrice Target$56.75 Short InterestProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Enanta Pharmaceuticals Short Interest DataCurrent Short Volume667,800 sharesPrevious Short Volume713,500 sharesChange Vs. Previous Month-6.41%Dollar Volume Sold Short$17.28 millionShort Interest Ratio / Days to Cover3.4Last Record DateMay 15, 2023Outstanding Shares21,060,000 sharesFloat Size19,340,000 sharesShort Percent of Float3.45%Today's Trading Volume129,061 sharesAverage Trading Volume241,133 sharesToday's Volume Vs. Average54% Short Selling Enanta Pharmaceuticals ? Sign up to receive the latest short interest report for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatENTA Short Interest Over TimeENTA Days to Cover Over TimeENTA Percentage of Float Shorted Over Time Enanta Pharmaceuticals (NASDAQ:ENTA) Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/2023667,800 shares $17.28 million -6.4%3.5%3.4 $25.87 4/30/2023713,500 shares $25.36 million -2.4%3.7%3.8 $35.55 4/15/2023730,800 shares $26.70 million +4.8%3.8%4.2 $36.53 3/31/2023697,100 shares $28.19 million -22.6%3.6%3.9 $40.44 3/15/2023900,100 shares $40.06 million +20.0%4.7%5.3 $44.51 2/28/2023750,300 shares $36.39 million -8.4%3.9%4.8 $48.50 2/15/2023819,500 shares $41.12 million -3.8%4.3%5.1 $50.18 1/31/2023851,400 shares $45.45 million +0.4%4.4%5.5 $53.38 1/15/2023847,700 shares $43.62 million -1.6%4.4%5 $51.46 12/30/2022861,500 shares $40.08 million -6.0%4.5%5 $46.52 12/15/2022916,400 shares $40.17 million -11.9%4.8%5.1 $43.84 11/30/20221,040,000 shares $45.54 million +4.2%5.4%5.4 $43.79 11/15/2022998,400 shares $47.14 million -4.0%5.2%4.9 $47.22 10/31/20221,040,000 shares $46.91 million -17.5%5.4%5.1 $45.11 10/15/20221,260,000 shares $59.16 million -2.3%6.5%6 $46.95 9/30/20221,290,000 shares $66.91 million -5.2%6.7%6.4 $51.87 9/15/20221,360,000 shares $78.77 million -8.1%7.0%6.1 $57.92 8/31/20221,480,000 shares $90.10 million -3.3%7.7%6.1 $60.88 8/15/20221,530,000 shares $107.80 million -8.9%7.9%6.1 $70.46 7/31/20221,680,000 shares $92.65 million +3.1%8.7%5.8 $55.15 7/15/20221,630,000 shares $83.64 million -1.8%8.4%5.9 $51.31 6/30/20221,660,000 shares $78.47 million +5.7%8.6%5.8 $47.27 6/15/20221,570,000 shares $62.80 million +6.1%10.7%5.8 $40.00 5/31/20221,480,000 shares $59.10 million +10.5%7.7%6.2 $39.93 5/15/20221,340,000 shares $66.84 million +10.7%6.9%5.5 $49.88 4/30/20221,210,000 shares $77.92 million +9.0%6.3%5.6 $64.40 4/15/20221,110,000 shares $82.42 million -5.9%5.8%5.2 $74.25 3/31/20221,180,000 shares $83.99 million +9.3%6.1%5.4 $71.18 3/15/20221,080,000 shares $70.87 million +21.9%5.6%5.1 $65.62 2/28/2022886,300 shares $62.41 million +13.7%4.6%4 $70.42 2/15/2022779,800 shares $48.51 million -16.5%4.1%3.5 $62.21 1/31/2022933,700 shares $55.48 million +28.6%5.2%4.3 $59.42 1/15/2022726,100 shares $43.57 million +4.0%N/A0 $60.00 12/31/2021697,900 shares $52.19 million -2.4%3.9%3.5 $74.78 12/15/2021715,300 shares $52.22 million +5.4%4.0%3.6 $73.00 11/30/2021678,900 shares $59.93 million -0.3%3.8%3.7 $88.28 11/15/2021681,000 shares $61.21 million -36.9%3.8%4 $89.88 10/29/20211,080,000 shares $92.72 million -32.1%6.1%6.7 $85.85 10/15/20211,590,000 shares $113.64 million -9.7%8.9%10.8 $71.47 9/30/20211,760,000 shares $99.99 million -2.8%9.9%11.8 $56.81 ENTA Short Interest - Frequently Asked Questions What is Enanta Pharmaceuticals' current short interest? Short interest is the volume of Enanta Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 667,800 shares of ENTA short. 3.45% of Enanta Pharmaceuticals' shares are currently sold short. Learn More on Enanta Pharmaceuticals' current short interest. What is a good short interest ratio for Enanta Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ENTA shares currently have a short interest ratio of 3.0. Learn More on Enanta Pharmaceuticals's short interest ratio. Which institutional investors are shorting Enanta Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Enanta Pharmaceuticals: Susquehanna International Group LLP, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Enanta Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.45% of Enanta Pharmaceuticals' floating shares are currently sold short. Is Enanta Pharmaceuticals' short interest increasing or decreasing? Enanta Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 667,800 shares, a drop of 6.4% from the previous total of 713,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Enanta Pharmaceuticals' float size? Enanta Pharmaceuticals currently has issued a total of 21,060,000 shares. Some of Enanta Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Enanta Pharmaceuticals currently has a public float of 19,340,000 shares. How does Enanta Pharmaceuticals' short interest compare to its competitors? 3.45% of Enanta Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Enanta Pharmaceuticals: Phathom Pharmaceuticals, Inc. (24.70%), Calliditas Therapeutics AB (publ) (0.02%), GH Research PLC (4.96%), Aldeyra Therapeutics, Inc (6.54%), Lexicon Pharmaceuticals, Inc. (3.40%), Phibro Animal Health Co. (2.23%), Arcutis Biotherapeutics, Inc. (33.67%), Evolus, Inc. (6.63%), Liquidia Co. (3.04%), Tyra Biosciences, Inc. (8.03%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Enbridge Inc. ($4.29 billion), T-Mobile US, Inc. ($4.17 billion), Charter Communications, Inc. ($3.07 billion), Occidental Petroleum Co. ($2.81 billion), Moderna, Inc. ($2.37 billion), Coinbase Global, Inc. ($2.27 billion), T. Rowe Price Group, Inc. ($1.98 billion), Verisk Analytics, Inc. ($1.94 billion), Extra Space Storage Inc. ($1.88 billion), and Xylem Inc. ($1.61 billion). View all of the most shorted stocks. What does it mean to sell short Enanta Pharmaceuticals stock? Short selling ENTA is an investing strategy that aims to generate trading profit from Enanta Pharmaceuticals as its price is falling. ENTA shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enanta Pharmaceuticals? A short squeeze for Enanta Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ENTA, which in turn drives the price of the stock up even further. How often is Enanta Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENTA, twice per month. The most recent reporting period available is May, 15 2023. More Short Interest Resources from MarketBeat Related Companies: Phathom Pharmaceuticals Short Interest Data Calliditas Therapeutics AB (publ) Short Interest Data GH Research Short Interest Data Aldeyra Therapeutics Short Interest Data Lexicon Pharmaceuticals Short Interest Data Phibro Animal Health Short Interest Data Arcutis Biotherapeutics Short Interest Data Evolus Short Interest Data Liquidia Short Interest Data Tyra Biosciences Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENTA) was last updated on 5/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.